Helix Biopharma Corp Stock Earnings Per Share
| HBP Stock | CAD 0.77 0.07 10.00% |
Helix BioPharma Corp fundamentals help investors to digest information that contributes to Helix BioPharma's financial success or failures. It also enables traders to predict the movement of Helix Stock. The fundamental analysis module provides a way to measure Helix BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Helix BioPharma stock.
Helix | Earnings Per Share |
Helix BioPharma Corp Company Earnings Per Share Analysis
Helix BioPharma's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Helix BioPharma Earnings Per Share | (1.05) X |
Most of Helix BioPharma's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Helix BioPharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Helix Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Helix BioPharma is extremely important. It helps to project a fair market value of Helix Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Helix BioPharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Helix BioPharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Helix BioPharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Helix Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Helix BioPharma Corp has an Earnings Per Share of -1.05 times. This is 112.54% lower than that of the Biotechnology sector and 78.08% lower than that of the Health Care industry. The earnings per share for all Canada stocks is 133.65% higher than that of the company.
Helix Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Helix BioPharma's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Helix BioPharma could also be used in its relative valuation, which is a method of valuing Helix BioPharma by comparing valuation metrics of similar companies.Helix BioPharma is currently under evaluation in earnings per share category among its peers.
Helix BioPharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Helix BioPharma from analyzing Helix BioPharma's financial statements. These drivers represent accounts that assess Helix BioPharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Helix BioPharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 59.7M | 69.0M | 114.4M | 40.6M | 51.2M | 97.2M | |
| Enterprise Value | 59.5M | 64.9M | 114.5M | 39.8M | 50.1M | 91.4M |
Helix Fundamentals
| Return On Equity | -22.21 | ||||
| Return On Asset | -4.59 | ||||
| Current Valuation | 36.67 M | ||||
| Shares Outstanding | 49.02 M | ||||
| Shares Owned By Insiders | 2.15 % | ||||
| Number Of Shares Shorted | 2.08 K | ||||
| Price To Earning | (7.09) X | ||||
| Price To Book | 77.46 X | ||||
| EBITDA | (9.22 M) | ||||
| Net Income | (9.26 M) | ||||
| Cash And Equivalents | 938 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 1.58 M | ||||
| Current Ratio | 0.37 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (5.22 M) | ||||
| Short Ratio | 0.30 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 2.5 | ||||
| Beta | -0.84 | ||||
| Market Capitalization | 37.75 M | ||||
| Total Asset | 1.49 M | ||||
| Retained Earnings | (210.67 M) | ||||
| Working Capital | (123 K) | ||||
| Net Asset | 1.49 M |
About Helix BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Helix BioPharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Helix BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Helix BioPharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Helix Stock
| 0.82 | GOOG | Alphabet CDR | PairCorr |
| 0.81 | TSLA | Tesla Inc CDR | PairCorr |
| 0.79 | NVDA | NVIDIA CDR | PairCorr |
| 0.78 | AMZN | Amazon CDR | PairCorr |
| 0.75 | WMT | Walmart Inc CDR | PairCorr |
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.